Halozyme Therapeutics (NASDAQ: HALO) received notice Thursday that the Blood Products Advisory Committee (BPAC) of the U.S. Food and Drug Administration voted in favor of HyQvia, which it was working with along with Baxter (NYSE: BAX).
The drug treats patients with primary immunodeficiency (PI), and according to the FDA, has a favorable risk/benefit profile. The vote was 15-1; HyQVia was previously approved for use in Europe in 2013.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
HyQvia is used in Europe as replacement therapy in adults who have primary immunodeficiency syndromes and in treatment for myeloma or leukemia.
After being halted, Halozyme has resumed trading and was recently up seven percent at $9.90. The shares had traded up to $10.70 on the open, but have since backed off. Given the recent run up in the price of Halozyme, FDA approval may have been priced in to a large degree.